GMP Corrective/Preventative Plans Will Get More FDA Attention – Baxter
Executive Summary
FDA's risk-based GMP initiative will require drug manufacturers to become more attentive to corrective and preventative action programs, Baxter Global Regulatory Affairs Director Lisa Skeens, PhD, said